NASDAQ:VCNXVaccinex Stock Price, Forecast & News

Vaccinex's stock was trading at $4.17 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, VCNX shares have decreased by 13.7% and is now trading at $3.60. View which stocks have been most impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vaccinex in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Vaccinex.

Vaccinex is scheduled to release its next quarterly earnings announcement on Wednesday, August 12th 2020. View our earnings forecast for Vaccinex.

Vaccinex Inc (NASDAQ:VCNX) issued its quarterly earnings results on Thursday, May, 14th. The company reported ($0.45) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.75) by $0.30. View Vaccinex's earnings history.

1 equities research analysts have issued 12-month price targets for Vaccinex's stock. Their forecasts range from $22.00 to $22.00. On average, they expect Vaccinex's share price to reach $22.00 in the next year. This suggests a possible upside of 511.1% from the stock's current price. View analysts' price targets for Vaccinex.

News stories about VCNX stock have trended negative on Tuesday, InfoTrie Sentiment Analysis reports. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Vaccinex earned a coverage optimism score of -2.1 on InfoTrie's scale. They also gave news articles about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the stock's share price in the near term. View the latest news about Vaccinex.

Some companies that are related to Vaccinex include XOMA (XOMA), Marinus Pharmaceuticals (MRNS), Aptinyx (APTX), TAIWAN LIPOSOME/S (TLC), Mallinckrodt (MNK), Immunic (IMUX), Lexicon Pharmaceuticals (LXRX), LifeVantage (LFVN), Aduro BioTech (ADRO), Kezar Life Sciences (KZR), NeuBase Therapeutics (NBSE), Strongbridge Biopharma (SBBP), Chimerix (CMRX), Aravive (ARAV) and Chiasma (CHMA). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Vaccinex investors own include Agile Therapeutics (AGRX), Aduro BioTech (ADRO), Crispr Therapeutics (CRSP), Exelixis (EXEL), VBI Vaccines (VBIV), vTv Therapeutics (VTVT), Opko Health (OPK), SCYNEXIS (SCYX), Sangamo Therapeutics (SGMO) and Whiting Petroleum (WLL).

(VCNX) raised $45 million in an initial public offering (IPO) on Thursday, August 9th 2018. The company issued 3,300,000 shares at a price of $12.00-$15.00 per share. Oppenheimer and BTIG acted as the underwriters for the IPO and Ladenburg Thalmann was co-manager.

Vaccinex trades on the NASDAQ under the ticker symbol "VCNX."

Shares of VCNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of VCNX stock can currently be purchased for approximately $3.60.

Vaccinex has a market capitalization of $59.94 million and generates $520,000.00 in revenue each year. The company earns $-31,860,000.00 in net income (profit) each year or ($2.47) on an earnings per share basis. Vaccinex employs 44 workers across the globe.

The official website for Vaccinex is www.vaccinex.com.

Vaccinex's mailing address is 1895 MOUNT HOPE AVENUE, ROCHESTER NY, 14620. The company can be reached via phone at 585-271-2700 or via email at [email protected]